Biogen’s New Alzheimer’s Drug Shows Promise in Phase 3 Trial

Trending News ☀️

Biogen Inc Stock Fair Value – Biogen ($NASDAQ:BIIB)’s new Alzheimer’s drug, Lecanemab, has shown promise in a recent Phase 3 clinical trial. The trial showed that patients who were treated with Lecanemab had a 27% greater reduction in cognitive and functional performance than those who were given a placebo. This is encouraging news for the millions of people worldwide who suffer from Alzheimer’s disease.

If Lecanemab is able to show a superior safety profile to Biogen’s previous Alzheimer’s drug, Aduhelm, it may be approved for use by the FDA. This would be a major win for Biogen and could help to recapture the company’s share price.

Share Price

The news has been mostly positive, and on Wednesday, BIOGEN INC stock soared by 39.8% from its previous closing price of 197.8. This is a promising sign for the future of the company and its ability to develop effective treatments for Alzheimer’s disease.

VI Analysis – Biogen Inc Stock Fair Value Calculator

A company’s fundamentals reflect its long term potential. The fair value of a company’s stock is determined by its future cash flows and earnings potential. The VI app makes it easy to analyze a company’s fundamentals and determine its fair value.

BIOGEN INC’s fair value is around $298.3, calculated by VI Line. The company’s stock is currently traded at $276.6, which is a fair price undervalued by 7%.

Summary

Biogen Inc. announced that its new Alzheimer’s disease drug, Aducanumab, met its primary endpoint in a Phase 3 clinical trial. Aducanumab is a monoclonal antibody that targets amyloid beta, a protein that is thought to play a role in the development of Alzheimer’s disease. The patients were randomized to receive either aducanumab or a placebo. This difference was even more pronounced in patients who had high levels of amyloid beta at baseline . Aducanumab also showed benefits on other measures of cognitive function and disease progression.

Biogen plans to submit these data to regulatory authorities in the United States and Europe later this year. If approved, Aducanumab would be the first drug to target amyloid beta and could represent a major advance in the treatment of Alzheimer’s disease. With no effective treatments currently available, there is a huge unmet need for new therapies for this devastating disease.